Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety Study of BAT2506 vs Simponi in Healthy Chinese Males
NCT05332730Phase 1Completed
- Sponsor
- Bio-Thera Solutions, Ltd.
- Start
- Aug 2022
- Primary completion
- Jun 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of BAT2506 in psoriatic arthritis (PsA) (3 arms), sponsored by Bio-Thera Solutions, Ltd. Primary endpoints: Maximum Plasma Concentration at Day 78 and Area Under the Concentration-Time Curve from time zero to infinity at Day 78. Started Aug 2022; status: completed.
02
Drugs
BAT2506
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on NCT05332730.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05332730.